Google
Trusted Resources: News & Events
Latest announcements and gatherings
Cydan Raises $34M to Advance New Therapies for Sickle Cell, Other Rare Diseases
Cydan, the company that founded Imara — which developed a sickle cell disease (SCD) treatment candidate, IMR-687 — has raised $34 million in new financing to advance innovative therapies for patients living with SCD and other rare diseases.
Cydan, based in Cambridge, Massachusetts, identifies promising scientific findings and drug candidates and advances them into clinical development. Cydan also establishes independent companies to promote selected therapies through clinical development and regulatory approval. In this round of financing, a new investor, Longitude Capital, joined existing investors New Enterprise Associates (NEA), Pfizer Venture Investments, Alexandria Venture Investments and Lundbeckfond Ventures.
+myBinderRelated Content
-
Sickle Cell Disease Management & Complications: Sophie Lanzkron MD of Johns HopkinsStuck on sickle cell disease? We hammer ...
-
Music therapy helps relieve pain in adults with sickle cell disease, pilot trial suggestsMusic therapy can help ease pain in ad...
-
Boston Children’s Hospital receives grant for sickle cell disease researchThe Bill and Melinda Gates Foundation aw...
-
Jennifer Doudna on ethics of gene editinghttps://www.youtube.com/watch?v=8Ijr1ccY...
-
The Hazards of Hazardous Drug Labeling: Time to Revisit Hydroxyurea?Despite benefits in reducing pain crises...
-
Spectra Optia Device Save Way to Treat Sickle Cell While Using Less Blood Cell Packs, Study FindsThe blood-separation device Spectra Opti...
-
Updated Mechanisms Underlying Sickle Cell Disease-Associated PainSickle cell disease (SCD) is one of the ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.